🚀 VC round data is live in beta, check it out!
J. Molner Valuation Multiples
Discover revenue and EBITDA valuation multiples for J. Molner and similar public comparables like WDB coco, Aligos Therapeutics, INmune Bio, Atara Biotherapeutics and more.
J. Molner Overview
About J. Molner
J.Molner AS is an Estonia-based company. The company is engaged in research and development in the field of biotechnology. The activities of the company are divided into two business segments: Generic Drugs and Services. It derives maximum revenue from Services.
Founded
2020
HQ
Employees
38
Website
Financials (FY)
EV
$41M
J. Molner Financials
J. Molner reported last fiscal year revenue of $1M and EBITDA of $1M.
In the same fiscal year, J. Molner generated $827K in gross profit, $1M in EBITDA, and $150K in net income.
J. Molner P&L
In the most recent fiscal year, J. Molner reported revenue of $1M and EBITDA of $1M.
J. Molner expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $827K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 61% | XXX | XXX | XXX |
| EBITDA | — | XXX | $1M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 76% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 26% | XXX | XXX | XXX |
| Net Profit | — | XXX | $150K | XXX | XXX | XXX |
| Net Margin | — | XXX | 11% | XXX | XXX | XXX |
| Net Debt | — | — | $622K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
J. Molner Stock Performance
J. Molner has current market cap of $40M, and enterprise value of $41M.
Market Cap Evolution
J. Molner's stock price is $23.72.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $41M | $40M | -2.2% | XXX | XXX | XXX | $0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJ. Molner Valuation Multiples
J. Molner trades at 30.2x EV/Revenue multiple, and 39.8x EV/EBITDA.
J. Molner Financial Valuation Multiples
As of April 21, 2026, J. Molner has market cap of $40M and EV of $41M.
Equity research analysts estimate J. Molner's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
J. Molner has a P/E ratio of 266.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $40M | XXX | $40M | XXX | XXX | XXX |
| EV (current) | $41M | XXX | $41M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 30.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 39.8x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 117.4x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 49.1x | XXX | XXX | XXX |
| P/E | — | XXX | 266.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (13.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified J. Molner Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
J. Molner Margins & Growth Rates
J. Molner's revenue in the last fiscal year declined by (50%).
J. Molner's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.
J. Molner Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (50%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 76% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (144%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
J. Molner Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| J. Molner | XXX | XXX | XXX | XXX | XXX | XXX |
| WDB coco | XXX | XXX | XXX | XXX | XXX | XXX |
| Aligos Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| INmune Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Atara Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Veru | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
J. Molner M&A Activity
J. Molner acquired XXX companies to date.
Last acquisition by J. Molner was on XXXXXXXX, XXXXX. J. Molner acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by J. Molner
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJ. Molner Investment Activity
J. Molner invested in XXX companies to date.
J. Molner made its latest investment on XXXXXXXX, XXXXX. J. Molner invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by J. Molner
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout J. Molner
| When was J. Molner founded? | J. Molner was founded in 2020. |
| Where is J. Molner headquartered? | J. Molner is headquartered in Estonia. |
| How many employees does J. Molner have? | As of today, J. Molner has over 38 employees. |
| Is J. Molner publicly listed? | Yes, J. Molner is a public company listed on Nasdaq Tallinn. |
| What is the stock symbol of J. Molner? | J. Molner trades under MOLNR ticker. |
| When did J. Molner go public? | J. Molner went public in 2022. |
| Who are competitors of J. Molner? | J. Molner main competitors are WDB coco, Aligos Therapeutics, INmune Bio, Atara Biotherapeutics. |
| What is the current market cap of J. Molner? | J. Molner's current market cap is $40M. |
| What is the current revenue of J. Molner? | J. Molner's last fiscal year revenue is $1M. |
| What is the current EV/Revenue multiple of J. Molner? | Current revenue multiple of J. Molner is 30.2x. |
| Is J. Molner profitable? | No, J. Molner is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.